Press Releases Sanofi

Equities

SAN

FR0000120578

Market Closed - Euronext Paris Other stock markets 11:35:14 2024-04-30 am EDT			After market 03:59:59 pm
93.08 ^EUR	+1.35%		92.2	-0.95%

10:42pm	First trial over Zantac cancer claims set to begin in Chicago	RE
06:00pm	Sanofi Announces Board and Committee Appointments	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Press Release: Annual General Meeting of April 30, 2024	12:00pm	GL
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024	07:20am	AQ
Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases	Apr. 26	PU
Sanofi Q1 robust 7% sales growth driven by launches, underpins full-year guidance	Apr. 26	AQ
Sanofi: Q1 Earnings Snapshot	Apr. 25	AQ
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance	Apr. 25	GL
AusBiotech announces incoming CEO	Apr. 24	AQ
Sanofi - Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 24	AQ
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 23	GL
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia	Apr. 23	AQ
The 2023 Pharmaceutical Patent Review	Apr. 17	AQ
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis	Apr. 17	GL
INNATE PHARMA ANNOUNCES ADVANCEMENT OF SANOFI-DEVELOPED NK CELL ENGAGER SAR443579/IPH6101 PROGRESSING TO PHASE 2 FOR BLOOD CANCER PATIENTS	Apr. 16	AQ
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents	Apr. 08	GL
AstraZeneca - Beyfortus approved in Japan for the prevention of RSV disease in infants	Mar. 28	AQ
Sanofi - Availability of the Q1 2024 Memorandum for modelling purposes	Mar. 25	AQ
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes	Mar. 22	GL
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes	Mar. 22	AQ
Manufacturing facility expansion to advance next-gen vaccine	Mar. 14	AQ
USPTO Updates Guidance On Enablement	Mar. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST